Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
89Bio Inc
(NQ:
ETNB
)
11.64
+0.33 (+2.92%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
840,223
Open
11.52
Bid (Size)
11.13 (1)
Ask (Size)
12.03 (1)
Prev. Close
11.31
Today's Range
11.59 - 11.69
52wk Range
6.575 - 22.93
Shares Outstanding
75,480,884
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
March 27, 2024
From
89bio, Inc.
Via
GlobeNewswire
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
March 17, 2024
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Via
The Motley Fool
Performance
YTD
+3.10%
+3.10%
1 Month
-0.85%
-0.85%
3 Month
+2.65%
+2.65%
6 Month
-24.61%
-24.61%
1 Year
-26.38%
-26.38%
More News
Read More
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
March 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
Analyst Ratings for 89bio
November 28, 2023
Via
Benzinga
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
March 07, 2024
Via
Benzinga
89bio to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
March 04, 2024
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 04, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 04, 2024
Via
InvestorPlace
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 04, 2024
Via
Benzinga
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
February 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
February 26, 2024
Via
Investor's Business Daily
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
January 12, 2024
Via
Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 12, 2023
From
89bio, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 07, 2023
Via
Benzinga
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
December 07, 2023
From
89bio, Inc.
Via
GlobeNewswire
Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
December 07, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
December 06, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
December 04, 2023
Via
Benzinga
Exposures
Product Safety
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
December 04, 2023
From
89bio, Inc.
Via
GlobeNewswire
89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
November 27, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.